The efficacy and safety of wedge resection for peripheral stage IA lung adenocarcinoma: a real-world study based on a single center

被引:3
|
作者
Bian, Dongliang [1 ]
Xiong, Yicheng [1 ]
Jin, Kaiqi [1 ]
Zhu, Yuming [1 ]
Yu, Huansha [2 ]
Dai, Jie [1 ]
Jiang, Gening [1 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, Shanghai, Peoples R China
[2] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Anim Expt Ctr, Shanghai, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
Lung adenocarcinoma stage IA; wedge resection; recurrence; SECTION COMPUTED-TOMOGRAPHY; LIMITED RESECTION; SUBLOBAR RESECTION; SURVIVAL OUTCOMES; CANCER; LOBECTOMY; IMPACT; CLASSIFICATION;
D O I
10.21037/jtd-22-1010
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The effectiveness of segmentectomy for stage IA lung adenocarcinoma (IA-LUAD) has been well-documented. However, the efficacy and safety of wedge resection for peripheral IA-LUAD remains controversial. This study evaluated the feasibility of wedge resection in patients with peripheral IA-LUAD. Methods: Patients with peripheral IA- LUAD who underwent wedge resection by video- assisted thoracoscopic surgery (VATS) at Shanghai Pulmonary Hospital were reviewed. Cox proportional hazards modeling was performed to identify predictors of recurrence. Receiver operating characteristic (ROC) curve analysis was used to calculate the optimal cutoffs of identified predictors. Results: A total of 186 patients (female/male, 115/ 71; mean age, 59.9 years) were included. Mean maximum dimension of consolidation component (MCD) was 5.6 mm, consolidation-to-tumor ratio (CTR) was 37%, and mean computed tomography value of tumor (CTVt) was -285.4 HU. With a median follow-up of 67 months (interquartile range, 52-72 months), the 5-year recurrence rate was 4.84%. Ten patients occurred recurrence postoperatively. No recurrence was observed adjacent to the surgical margin. Increasing MCD, CTR, and CTVt were associated with a higher risk of recurrence, with corresponding hazard ratios (HRs) of 1.212 [95% confidence interval (CI): 1.120-1.311], 1.054 (95% CI: 1.018-1.092), and 1.012 (95% CI: 1.004-1.019) with optimal cutoffs for predicting recurrence of 10 mm, 60%, and -220 HU, respectively. When a tumor had characteristics under these respective cutoffs, no recurrence was observed. Conclusions: Wedge resection can be considered to be a safe and efficacious management strategy for patients with peripheral IA-LUAD, especially for MCD less than 10 mm, CTR less than 60% and CTVt less than -220 HU.
引用
收藏
页码:54 / 64
页数:11
相关论文
共 50 条
  • [41] Real-world efficacy and safety of BRAF-targeted therapy for patients with advanced melanoma: A single-center retrospective study in Japan
    Nakano, Eiji
    Takahashi, Akira
    Ogata, Dai
    Namikawa, Kenjiro
    Yamazaki, Naoya
    JOURNAL OF DERMATOLOGY, 2024, 51 (09): : 1199 - 1207
  • [42] Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
    Li, Gaojie
    Gu, Yuanxia
    Zou, Qin
    Wang, Yiyi
    Xiao, Yue
    Xia, Dengmei
    Zhan, Tongying
    Zhou, Xingli
    Wang, Qian
    Yan, Wei
    Li, Wei
    DERMATOLOGY AND THERAPY, 2022, 12 (09) : 2105 - 2115
  • [43] Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
    Gaojie Li
    Yuanxia Gu
    Qin Zou
    Yiyi Wang
    Yue Xiao
    Dengmei Xia
    Tongying Zhan
    Xingli Zhou
    Qian Wang
    Wei Yan
    Wei Li
    Dermatology and Therapy, 2022, 12 : 2105 - 2115
  • [44] Efficacy and safety of immune checkpoint inhibitor rechallenge in advanced lung cancer: A multicenter, real-world study
    Jin, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S851 - S852
  • [45] Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
    Zhang, Kun
    Ma, Xiya
    Gao, Hongjun
    Wang, Hong
    Qin, Haifeng
    Yang, Shaoxing
    Liu, Xiaoqing
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3409 - 3417
  • [46] A Real-World Study: Efficacy and Safety of Anlotinib for Advanced Non-Small Cell Lung Cancer
    Wang, J.
    Yi, T.
    Dong, Y.
    Ran, R.
    Cao, F.
    Li, Y.
    Luo, Z.
    Xu, Y.
    Fu, Y.
    Kuang, L.
    Chen, G.
    Qu, G.
    Yin, Y.
    Li, J.
    Xu, X.
    Chen, Y.
    Song, Q.
    Chu, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1071 - S1071
  • [47] Early Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: A Single-Center Study
    Liu, Esther
    Mandel, Jordan
    Battat, Robert
    Longman, Randy
    Scherl, Ellen
    Lukin, Dana
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S759 - S760
  • [48] Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single center, retrospective, real-world study
    Fang, Fang
    Duan, Hongmei
    Ding, Shuang
    CLINICAL RHEUMATOLOGY, 2025, 44 (03) : 1113 - 1122
  • [49] Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
    Huang, Kaituo
    Liu, Jing
    Xia, Wenhao
    Tian, Chuwen
    Yao, Lingya
    Cao, Qian
    Chen, Haotian
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [50] Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    JOURNAL OF DERMATOLOGY, 2024, 51 (05): : 649 - 658